Post hoc exploratory analysis of the effect of foslevodopa/foscarbidopa continuous subcutaneous infusion on nocturia in patients with Parkinson’s disease
Clinical Parkinsonism & Related Disorders · 2025 · 12 · 100330
DOI: 10.1016/j.prdoa.2025.100330 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Parkinsonism & Related Disorders, 2025. Verfasst von K Ray Chaudhuri und 8 weiteren Autor:innen. Beteiligte Einrichtung: Parkinson's Foundation Centre of Excellence, King's College Hospital, London, UK. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie Inc.
Abstract (Originalsprache)
Introduction
Parkinson's disease (PD) non-motor symptom burden, including nocturia and sleep disturbances, worsens with disease progression. Continuous dopaminergic drug delivery with nocturnal infusion in PD demonstrated improvements in sleep and nocturia. Foslevodopa/foscarbidopa (LDp/CDp) provides 24-hour continuous drug delivery of levodopa/carbidopa (LD/CD) prodrugs via continuous subcutaneous infusion (CSCI).
Methods
Least-squares mean nocturia changes (measured via Parkinson's Disease Sleep Scale-2 item 8) in patients with PD from a randomized 12-week phase 3 trial of LDp/CDp CSCI versus oral LD/CD (NCT04380142) and a 52-week open-label LDp/CDp CSCI phase 3 trial (NCT03781167) were analyzed post hoc via mixed-effects regression and analysis of covariance. Correlation coefficients at baseline (BL) and in change from BL to week 12 or week 52 (Δ BL-wk 12 or Δ BL-wk 52) for nocturia and quality of life (QoL, measured as Parkinson's Disease Questionnaire [PDQ-39] Summary Index score) were calculated via Spearman's test.
Results
This exploratory analysis demonstrated significant and sustained improvement in nocturia symptoms from BL with LDp/CDp treatment in both the randomized (to week 12; n = 44; nominal p ≤ 0.01) and open-label (to weeks 6, 13, 26, and 52; with n = 176, 149, 107, and 75, respectively; nominal p ≤ 0.001 for all) trials. Nocturia improvement was significantly greater in LDp/CDp- versus oral-treated patients (n = 59; nominal p ≤ 0.05). A significant positive correlation between nocturia and QoL was shown at BL and between Δ BL-wk 12 in the randomized trial (nominal p ≤ 0.05 for both), while open-label results showed no significant correlations.
Conclusions
LDp/CDp-treated patients with PD demonstrated significantly improved nocturia with 24-hour therapy, 12-week nocturia improvements were significantly greater than oral therapy, and patient-reported nocturia may correlate with QoL.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Parkinson's Foundation Centre of Excellence, King's College Hospital, London, UK.
- Parkinson's Centre of Excellence, King's College Hospital, London, Dubai, UAE.
- King's College, London, UK.
- Dementech Neuroscience Clinical Academic Centre, London, UK.
- Clinique Neuro-Lévis, Université Laval, Lévis, QC, Canada.
- Centre de Recherche St-Louis, Lévis, QC, Canada.
Förderung
- AbbVie Inc
Zitieren
APA
Chaudhuri, K. R., Bouchard, M., Freire-Alvarez, E., Pahwa, R., Bergmann, L., Gupta, R., Kukreja, P., Shah, M. B., & Isaacson, S. H. (2025). Post hoc exploratory analysis of the effect of foslevodopa/foscarbidopa continuous subcutaneous infusion on nocturia in patients with Parkinson’s disease. Clinical Parkinsonism & Related Disorders, 12, 100330. https://doi.org/10.1016/j.prdoa.2025.100330
Vancouver
Chaudhuri KR, Bouchard M, Freire-Alvarez E, Pahwa R, Bergmann L, Gupta R, et al. Post hoc exploratory analysis of the effect of foslevodopa/foscarbidopa continuous subcutaneous infusion on nocturia in patients with Parkinson’s disease. Clinical Parkinsonism & Related Disorders. 2025;12:100330. doi:10.1016/j.prdoa.2025.100330
BibTeX
@article{Chaudhuri2025,
author = {Chaudhuri, K Ray and Bouchard, Manon and Freire-Alvarez, Eric and Pahwa, Rajesh and Bergmann, Lars and Gupta, Resmi and Kukreja, Pavnit and Shah, Megha B and Isaacson, Stuart H},
title = {Post hoc exploratory analysis of the effect of foslevodopa/foscarbidopa continuous subcutaneous infusion on nocturia in patients with Parkinson’s disease},
journal = {Clinical Parkinsonism & Related Disorders},
year = {2025},
volume = {12},
pages = {100330},
doi = {10.1016/j.prdoa.2025.100330}
}
EUVIMED